Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Les Laboratoires Servier, 50, rue Carnot, 92284, Suresnes cedex, France
Valdoxan 25 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Orange-yellow, oblong, 9.5 mm long, 5.1 mm wide film-coated tablet with blue imprint of company logo on one side. |
Each film-coated tablet contains 25 mg of agomelatine.
Excipient with known effect: Each film-coated tablet contains 61.8 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Film-coating: Hypromellose Printing ink containing shellac, propylene glycol and indigo carmine aluminium lake (E132). |
Aluminium/PVC blister packed in cardboard boxes.
Calendar packs containing 14, 28, 56, 84 and 98 film-coated tablets.
Calendar packs of 100 film-coated tablets for hospital use.
Not all pack sizes may be marketed.
Les Laboratoires Servier, 50, rue Carnot, 92284, Suresnes cedex, France
EU/1/08/499/002
EU/1/08/499/003
EU/1/08/499/005
EU/1/08/499/006
EU/1/08/499/007
EU/1/08/499/008
Date of first authorisation: 19 February 2009
Date of latest renewal: 13 November 2013
| Drug | Countries | |
|---|---|---|
| VALDOXAN | Austria, Brazil, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.